Showing results (2991-3000 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 14, 2022
Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexesTinnabhop Santadkha, Wanwisa Skolpap, Remant K C, et al.
Investigational New Drugs|July 14, 2022
Antitumor activity of mianserin (a tetracyclic antidepressant) primarily driven by the inhibition of SLC1A5-mediated glutamine transportZelin Duan, Zhiyun Zhou, Feifei Lu, et al.
Investigational New Drugs|January 1, 1986
Activity of tricyclic nucleoside 5'-phosphate in model systems of human ovarian cancerB C Behrens, T C Hamilton, K G Louie, et al.
Investigational New Drugs|January 1, 1986
Clinical pharmacology of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193)R M Green, D J Stewart, J A Maroun
Investigational New Drugs|July 4, 2019
A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis inductionMohammadali Soleimani Damaneh, Jian-Ping Hu, Xia-Juan Huan, et al.
Investigational New Drugs|June 27, 2019
Anticancer activity of a novel methylated analogue of L-mimosine against an in vitro model of human malignant melanomaSotiris Kyriakou, Melina Mitsiogianni, Theodora Mantso, et al.
Investigational New Drugs|February 12, 2022
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumorsSaiama N Waqar, Clifford Robinson, Anthony J Olszanski, et al.
Investigational New Drugs|September 29, 2018
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastasesHani M Babiker, Sara A Byron, William P D Hendricks, et al.
Investigational New Drugs|September 8, 2018
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Investigational New Drugs|September 8, 2018
Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II studyPedro C Barata, Matthew Cooney, Prateek Mendiratta, et al.
Pageof 372